Distribution dependence
The company relies on wholesalers, pharmacies and channel partners to reach end customers.
- Scope
- Europe and North America sales channels
- Materiality
- high
Nosa Plugs
Nosa Plugs AB is a Swedish listed group built around patented slow-release technology that incorporates substances into plastic products. Through its subsidiaries, the company develops, markets and distributes niche consumer and healthcare products, including intranasal and odor-control offerings, in Europe and the United States.
| % | |
|---|---|
| Nasal care products | 35% Products such as Nozoil and related nasal-care offerings sold through pharmacy and other channels. |
| Odor control products | 25% Products designed to reduce or manage odor-related issues for consumer and healthcare use. |
| Microbial control products | 15% Products positioned for hygiene and microbial management applications. |
| Smell training products | 10% Products and programs intended to support olfactory rehabilitation and training. |
| Drug delivery platform | 15% Proprietary intranasal delivery technology used to enable new product development and licensing opportunities. |
Nosa sells through both B2B and B2C channels, with pharmacies, wholesalers, distributors and healthcare buyers forming...
- Pharmacies and pharmacy chainsprimary
They buy Nozoil and consumer health products for retail and online pharmacy sales.
- Pharmaceutical wholesalersprimary
They distribute NOSA products into national pharmacy networks and extend market access.
- Consumersprimary
They purchase nasal-care, odor-control and smell-training products for personal use.
- Healthcare institutions and regionssecondary
They buy selected products for clinical or institutional use through procurement channels.
- Distributors and channel partnerssecondary
They buy or resell products to build country-level coverage and market entry.
The group reports sales primarily in Europe and the United States, with operations structured around selected country...
- •Sales are concentrated in Europe and the USA
- •Country launches are used to build pharmacy-channel coverage
- •Local wholesalers expand access in each national market
- •The US subsidiary supports North American commercialization
- •Geographic mix affects regulatory, currency and distribution exposure
Nosa’s strategy is to combine internal product development with selective acquisition of niche brands and products that...
01
Expand pharmacy distribution in Europeshort-term
Pharmacy access is central to reaching consumers efficiently and building recurring product sales.
02
Develop and validate the technology platformmedium-term
The patented slow-release platform underpins future product innovation and potential licensing value.
03
Acquire niche products and brandsmedium-term
Acquisitions can add products that fit existing channels and improve commercial leverage.
The business depends on distributors, suppliers and patent protection, so commercial execution and...
Patent and IP protection
Products and the platform are based on proprietary technology that may be difficult to fully protect.
- Scope
- New products and drug-delivery platform
- Materiality
- high
Financing and liquidity needs
Product development and commercialization can require external funding before scale is reached.
- Scope
- Group-level cash flow
- Materiality
- high
Supplier and raw-material dependence
Manufacturing and packaging require reliable third-party inputs and logistics.
- Scope
- Product supply chain
- Materiality
- medium
Foreign exchange volatility
International sales and costs create currency exposure across markets.
- Scope
- SEK, EUR and USD mix
- Materiality
- medium
Goodwill impairment
Could materially affect equity and operating results
Acquisition accounting for Pharmacure
Affects reported asset base and earnings profile
Warrants and share-based dilution
Affects equity and per-share analysis
Intra-group eliminations
Important for understanding consolidated revenue
: 11/08/2026